Moving away from pharma’s paternalistic approach
September 12, 2018 | Patient-centric, Patient-centricity, life sciences, patient engagement
New handbook makes the case for greater patient engagement in the development of new medicines
12 September 2018, Cambridge, UK—The pharmaceutical industry has achieved great success in delivering innovative medicines, but life science companies must become ever more consumer-centric if they are to realise the step change in improving patient outcomes that their science promises, according to a new patient engagement handbook released today. 
Patient Engagement for the Life Sciences by Guy Yeoman and Mitchell Silva explains the ‘why’ and the ‘how’ of patient engagement, presenting the compelling argument for why life science companies need to embrace and partner with patients and outlining an operating framework for doing it effectively.
“It’s so important to shift from patient-centric rhetoric to an integrated model where life cycle decisions are informed by patient insight and patient solutions are created with patients,” Yeoman commented.
Guy Yeoman has worked for the last two decades in the pharmaceutical industry, and in the last three years he built a patient-engaging capability in a large pharma organisation. Mitchell Silva is a patient expert and Chair of the European Patients’ Academy (EUPATI) in Belgium. They are co-founders of MediPaCe, a strategic consultancy that works with the life science industry to make patient engagement a reality. 
In Patient Engagement for the Life Sciences, the authors discuss the future of the pharmaceutical industry and how a number of drivers — including digital technology, patient expectations, outcomes-based payments and spiralling R&D costs — will make co-creating medicines with patients crucial to pharma companies’ ability to continue to deliver patient value.
It goes on to describe the framework necessary for embedding patient engagement into business practice, and the process for transforming into a company with patients at the centre of its culture.
Silva said, “Patients increasingly want to contribute to the development of better medicines and better services to support new treatments, but often the infrastructure to involve patients in a structural way is lacking. Patients are waiting to contribute.”
Cuttsy+Cuttsy provided editorial support, cover design and illustrations for the publication. Director Caroline Benson said, “As a healthcare communications agency where people matter, Guy and Mitchell’s book aligned perfectly with our company values. We were delighted to help bring it to life, as working with patients to make sure products and services work for them is what we have always done, and we truly believe that it gives the best results for everyone.”
Patient Engagement for the Life Sciences is now available as an eBook. Any profits generated from book sales will be donated to International Health Partners UK, Europe’s largest coordinator of donated medicines, to support patients around the world.
Download your copy from www.medipace.com/book
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Another year, another B!
Louise Jones, Cuttsy+Cuttsy's Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.
Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director
Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.
Clinical trial considerations: Why supporting HCPs matters...
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.
Clinical trial considerations: Why diversity matters...
Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...
Clinical trial considerations: Why digital matters...
Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.
Clinical trials explained: Why imagery matters...
Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...
Clinical trials explained: Why health literacy matters...
Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...
Clinical trials explained: Why iconography matters...
Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...
Cuttsy+Cuttsy appoints Harriet Karia as Managing Director
Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.
Using generative AI in healthcare comms - our promise to our clients
It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when...